Windtree Therapeutics Stock Today

WINT Stock  USD 0.37  0.02  5.71%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Over 80

 
100  
 
Zero
High
Windtree Therapeutics is selling for under 0.37 as of the 28th of March 2024; that is 5.71% increase since the beginning of the trading day. The stock's last reported lowest price was 0.34. Windtree Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Windtree Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2022 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
8th of August 1995
Category
Healthcare
Classification
Health Care
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. The company has 9.18 M outstanding shares of which 30.48 K shares are at this time shorted by private and institutional investors with about 0.31 trading days to cover. More on Windtree Therapeutics

Moving together with Windtree Stock

  0.71MBRX Moleculin Biotech Upward RallyPairCorr
  0.72MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.68KA Kineta Inc Report 29th of March 2024 PairCorr

Moving against Windtree Stock

  0.92MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.9DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.84MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.76EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.67MDWD Mediwound Financial Report 4th of June 2024 PairCorr
  0.62URGN UroGen Pharma Financial Report 9th of May 2024 PairCorr
  0.48TCRX Tscan Therapeutics Financial Report 8th of May 2024 PairCorr

Windtree Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Windtree Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Windtree Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEOSten Karlsson
Old NameWest International AB (publ)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Windtree Therapeutics report their recommendations after researching Windtree Therapeutics' financial statements, talking to executives and customers, or listening in on Windtree Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Windtree Therapeutics. The Windtree consensus assessment is calculated by taking the average forecast from all of the analysts covering Windtree Therapeutics.
Financial Strength
Based on the key indicators related to Windtree Therapeutics' liquidity, profitability, solvency, and operating efficiency, Windtree Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of Windtree Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00140.0015
Notably Down
Pretty Stable
Total Current Liabilities2.7 M2.8 M
Notably Down
Slightly volatile
Non Current Liabilities Total30.8 M29.3 M
Sufficiently Up
Slightly volatile
Total Assets42.5 M43.6 M
Fairly Down
Slightly volatile
Total Current Assets8.1 M8.5 M
Notably Down
Slightly volatile
Windtree Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Windtree Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Windtree Therapeutics' financial leverage. It provides some insight into what part of Windtree Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Windtree Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Windtree Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Windtree Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.28 M in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Windtree Therapeutics has a current ratio of 2.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Windtree Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Windtree Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Windtree Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Windtree to invest in growth at high rates of return. When we think about Windtree Therapeutics' use of debt, we should always consider it together with cash and equity.

Net Income

(26.07 Million)
Windtree Therapeutics (WINT) is traded on NASDAQ Exchange in USA. It is located in 2600 Kelly Road, Warrington, PA, United States, 18976-3622 and employs 20 people. Windtree Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.38 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Windtree Therapeutics's market, we take the total number of its shares issued and multiply it by Windtree Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Windtree Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.18 M outstanding shares of which 30.48 K shares are at this time shorted by private and institutional investors with about 0.31 trading days to cover. Windtree Therapeutics currently holds about 11.38 M in cash with (13.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37.
Check Windtree Therapeutics Probability Of Bankruptcy
Ownership Allocation
Windtree Therapeutics owns a total of 9.18 Million outstanding shares. Windtree Therapeutics maintains 4.65 (%) of its outstanding shares held by insiders and 12.91 (%) owned by institutional investors. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Windtree Ownership Details

Windtree Stock Price Odds Analysis

Attributed to a normal probability distribution, the odds of Windtree Therapeutics jumping above the current price in 90 days from now is about 75.56%. The Windtree Therapeutics probability density function shows the probability of Windtree Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Windtree Therapeutics has a beta of -0.6714. This entails as returns on benchmark increase, returns on holding Windtree Therapeutics are expected to decrease at a much lower rate. During the bear market, however, Windtree Therapeutics is likely to outperform the market. Additionally, windtree Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 0.37HorizonTargetOdds Above 0.37
24.37%90 days
 0.37 
75.56%
Based on a normal probability distribution, the odds of Windtree Therapeutics to move above the current price in 90 days from now is about 75.56 (This Windtree Therapeutics probability density function shows the probability of Windtree Stock to fall within a particular range of prices over 90 days) .

Windtree Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Windtree Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Windtree Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Windtree Therapeutics' value.
InstituionRecorded OnShares
Citadel Advisors Llc2023-09-30
0.0
Two Sigma Securities, Llc2023-09-30
0.0
Alyeska Investment Group, L.p.2023-09-30
136.5 K
Vanguard Group Inc2023-12-31
41.6 K
Virtu Financial Llc2023-12-31
38.9 K
Geode Capital Management, Llc2023-12-31
14.2 K
Ubs Group Ag2023-12-31
510
Wells Fargo & Co2023-12-31
32.0
U.s. Bancorp2023-12-31
3.0
Morgan Stanley - Brokerage Accounts2023-12-31
2.0
Advisor Group Holdings, Inc.2023-12-31
1.0
View Windtree Therapeutics Diagnostics

Windtree Therapeutics Historical Income Statement

Windtree Therapeutics Income Statement is one of the three primary financial statements used for reporting Windtree's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Windtree Therapeutics revenue and expense. Windtree Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Windtree Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 29.4 M in 2024, whereas Operating Income is likely to drop (16.8 M) in 2024. View More Fundamentals

Windtree Stock Against Markets

Picking the right benchmark for Windtree Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Windtree Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Windtree Therapeutics is critical whether you are bullish or bearish towards Windtree Therapeutics at a given time. Please also check how Windtree Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Windtree Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Windtree Therapeutics Corporate Directors

Windtree Therapeutics corporate directors refer to members of a Windtree Therapeutics board of directors. The board of directors generally takes responsibility for the Windtree Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Windtree Therapeutics' board members must vote for the resolution. The Windtree Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Windtree Stock?

Before investing in Windtree Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Windtree Therapeutics. To buy Windtree Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Windtree Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Windtree Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Windtree Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Windtree Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Windtree Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Windtree Stock please use our How to Invest in Windtree Therapeutics guide.

Already Invested in Windtree Therapeutics?

The danger of trading Windtree Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Windtree Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Windtree Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Windtree Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Windtree Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Windtree Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Windtree Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Windtree Therapeutics Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Windtree Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Windtree Stock please use our How to Invest in Windtree Therapeutics guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for Windtree Stock analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Correlations
Find global opportunities by holding instruments from different markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Windtree Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Windtree Therapeutics. If investors know Windtree will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Windtree Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(16.79)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.23)
Return On Equity
(1.99)
The market value of Windtree Therapeutics is measured differently than its book value, which is the value of Windtree that is recorded on the company's balance sheet. Investors also form their own opinion of Windtree Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Windtree Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Windtree Therapeutics' market value can be influenced by many factors that don't directly affect Windtree Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Windtree Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Windtree Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Windtree Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.